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NeuroprotectionAbstract Background: Alzheimer’s disease (AD) is a complex neurodegenerative disease charac-
terized by progressive decline in memory, language and other cognitive functions. Recent studies
provide convincing evidence on the role of vitamin D3 on the nervous system.
Aim: To investigate the effect of the active form of vitamin D3 (1,25-dihydroxycholecalciferol) as a
neuroprotective agent in experimentally induced AD in rats.
Methods: 40 adult male Wistar (albino) rats weighing 180 to 200 g were included in this study. Rats
were divided into four groups (each of 10 rats): Group I: normal healthy rats receiving intracere-
broventricular injection (icv) of artiﬁcial cerebrospinal ﬂuid (ACSF) and serving as a control group.
Group II: rats with induced AD by icv colchicine injection of 15 lg/rat bilaterally and receiving no
treatment. Group III: rats pre-treated with active form of vitamin D3 42 IU/kg/day subcutaneously
(s.c.) for one week followed by induction of AD then post-treated with vitamin D3 in the same dose
for 3 weeks. Group IV: rats with induced AD then post-treated with vitamin D3 for 3 weeks.
The following parameters were evaluated in rats of all studied groups:
128 A.R. Mohamed et al.1- Behavioral assessment: Morris water maze and open ﬁeld tasks were performed at days
13, 14 and 21 post-icv injection for assessing cognitive, gross behavioral and motor
activities of studied groups.
2- Biochemical tests: Hippocampal tissue levels of brain derived neurotrophic factor
(BDNF), amyloid beta (Ab) peptide, and antioxidant system; glutathione reductase
(GR) and glutathione peroxidase (GPX).
Results: The present study revealed a signiﬁcant increase in time latency of water maze test and
hippocampal tissue level of Ab peptide concomitant with signiﬁcant reduction of hippocampal tis-
sue levels of BDNF, GR and GPX, in untreated AD rats (group II) versus control ACSF-injected
rats (group I) and vitamin D3-treated AD rats (groups III and IV). However, group III (AD rats
pre- and post-treated with vitamin D3) showed a signiﬁcant decrease in time latency and Ab pep-
tide, and a signiﬁcant elevation of BDNF, GR and GPX, versus group IV (AD rats post-treated
with vitamin D3).
Conclusion: Prophylactic use of active form of vitamin D3 (1,25(OH)2D3) appears to possess a
neuroprotective effect in AD involving various mechanisms. Hence, vitamin D3 or its analogues
can be considered as promising agents for development of new prophylactic and therapeutic neuro-
protectors.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Alzheimer’s disease (AD) is a complex neurodegenerative dis-
ease characterized by progressive decline in memory, language
and other cognitive functions. Several etiologic hypotheses
have been advanced for AD as genetic defects, appearance of
neuroﬁbrillary tangles, altered amyloid precursor processing,
deﬁciency of neurotropic factors, mitochondrial defect, trace
element neurotoxicity, energy metabolism deﬁcit and oxidative
stress.1
The hippocampus, a key region of the medial temporal
lobe, is a frequent target in many neurological diseases and
most forms of dementia. It is well established that damage to
the hippocampus accounts for many of the cognitive deﬁcits
observed in AD, particularly those concerned with long term
memory.2
Alzheimer’s disease is associated with microtubule dysfunc-
tion and characterized by the appearance of speciﬁc cytoskel-
etal cellular abnormalities, which are associated with
cognitive impairment.3 Colchicine is a microtubule-disrupting
agent that produces marked destruction of hippocampal gran-
ule cells, mossy ﬁbers and septo-hippocampal pathways. It
induces neuroﬁbrillary degeneration by binding to tubulin,
the structural protein of the microtubule, which is associated
with loss of cholinergic neurons and decrease in acetylcholine
transferase, thereby, resulting in impairment of learning and
memory. Colchicine-induced cognitive impairment has been
established as an animal model of sporadic dementia of Alzhei-
mer’s type.4
Oxidative stress, due to increased free radical generation
and impairment of the endogenous antioxidant mechanisms,
is an important factor that has been implicated in neuronal
damage of AD and cognitive defects seen in elderly.5
An abnormally elevated level of the amyloid beta (Ab) pep-
tide in the brain is one of the prominent features of AD. Ab
peptide is normally produced by neurons and cleared through
its degradation by the proteinase enzyme within the brain tis-
sues, as well as, through its elimination from the brain to the
circulating blood via an efﬂux transport system at the bloodbrain barrier (BBB). It has been proposed that impairment
of cerebral clearance of Ab peptide leads to abnormal eleva-
tion of its brain level in late onset AD, which accounts for
more than 90% of all cases of AD.6 Indeed, cerebrovascular
dysfunction has been implicated to cause impairment of Ab
peptide clearance across BBB; likewise, low levels of vitamin
D3 are associated with increased risk of AD, as well as, vascu-
lar disorders.7
Traditionally, vitamin D3 was considered as a hor-
monal regulator of calcium and phosphate homeostasis;
however, results from recent studies provide a convincing
evidence on the role of vitamin D3 in other biochemical
processes in various tissues, including the nervous
system.8
Therefore, the aim of the present work was to investigate
and assess the possible neuroprotective effect of the active
form of vitamin D3 (1,25-dihydroxycholecalciferol) in colchi-
cine-induced AD in rats.
2. Materials and methods
This study was carried out on 40 adult male Wistar (albino)
rats weighing 180–200 g. The animals were housed under stan-
dard laboratory conditions with natural light/dark cycle with
free access to standard diet and water throughout the experi-
mental period. All the experiments were held between 9:00
and 15:00 h. The study protocol was approved by Ethics Com-
mittee of Faculty of Medicine, Alexandria University, and
conducted in Physiology, Clinical Pharmacology and Medical
Biochemistry Departments, Faculty of Medicine, Alexandria
University.
Animals were divided into 4 groups (each of 10 rats); as
follows:
 Group I (Control ACSF-injected): included normal
healthy rats that received intracerebroventricular (icv)
artiﬁcial cerebrospinal ﬂuid (ACSF) 5 ll/site/rat. ACSF
constituents in milli mole (mM): 147 NaCl, 2.9 KCl,
1.6 MgCl2, 1.7 CaCl2 and 2.2 dextrose.
9
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AD by icv injection of colchicine dissolved in ACSF
15 lg/rat (7.5 lg in 5 ll/site), bilaterally into the lateral
ventricle using Hamilton microsyringe.10
 Group III (Vitamin D3 pre- and post-AD treated): rats in
this group received active form of vitamin D3 (1,25-dihy-
droxycholecalciferol) (1,25(OH)2D3) in a daily dose of
42 IU/kg subcutaneously (s.c.) for one week,11 followed
by induction of AD by icv injection of colchicine as pre-
viously mentioned.10 Then, rats received the same daily
dose of 1,25(OH)2D3 for 3 weeks.
11
 Group IV (Vitamin D3 post-AD treated): included rats
with induced AD, as previously mentioned, followed
by administration of the same daily dose of
1,25(OH)2D3 for 3 weeks (42 IU/kg s.c.).
11
Animals were anesthetized with thiopental sodium 45 mg/
kg, intraperitoneally (i.p.), then surgery was performed accord-
ing to the previously described protocol using a stereotaxic
apparatus (Kopf, Germany).9,10 The coordinates of the icv
cannula implantation were 0.8 mm posterior to the bregma,
1.8 mm lateral to the sagittal suture and 3.6 mm beneath the
cortical surface. After surgery, rats received gentamycin
(5 mg/kg, i.p.) to prevent sepsis and were provided with special
care and were monitored until spontaneous movement
occurred.
Colchicine was obtained from Sigma–Aldrich, St. Louis,
USA and was dissolved in ACSF. Vitamin D3
(1,25(OH)2D3) was obtained from Calbiochem, CA, USA
and was prepared daily and dissolved in 1% ethanol (diluted
with sterile saline). All other chemicals were analytical grade
commercial products.
2.1. Behavioral assessment
2.1.1. Assessment of cognitive performance4–10
The acquisition and retention of a spatial navigation task were
assessed using Morris water maze. Animals were trained to
swim to a platform in a circular pool (180 cm diame-
ter · 60 cm), ﬁlled with water (28 ± 2 C) to a depth of
40 cm. The pool was divided into 4 quadrants by 4 starting
points marked on its wall: North, South, East and West (N–
S–E–W). A circular platform 9 cm in diameter was placed in
the pool 2 cm below water level mounted on a column. The
platform provided the only escape from water and was ﬁxed
in the center of one of the 4 quadrants for the duration of
experiment. A colored ﬂag was placed outside the pool in a
ﬁxed position relative to the pool to help the rat to locate
the position of the platform hidden below the water.
(a) Maze acquisition phase (training): On day 13 post-icv
injection, rats received a training session consisting of
4 trials with an interval of 10 min. In all 4 trials, the
starting positions were different. The time taken by a
rat to reach the platform was recorded as initial acquisi-
tion latency (IAL) up to a maximum of 120 s (s).
(b) Maze retention phase (testing for retention of the learned
task): Following 24 h (day 14) and 8 days (day 21) after
IAL, each rat was randomly released at any one of the
starting points (N–S–E–W) facing the wall of the pool
and tested for the retention of the learnt task. Thelatency to reach the hidden platform on days 14 and
21 was recorded and termed as ﬁrst and second retention
latency (1st RL and 2nd RL) respectively.
2.1.2. Assessment of gross behavioral activity12
On days 13, 14 and 21 post-icv injection, the gross behavioral,
and spontaneous motor activities of rats were assessed in open
ﬁeld arena. The open ﬁeld chamber is a wooden box
(72 · 72cm · 36 cm height) with one wall formed of glass and
its ﬂoor is divided into equal-sized squares. Open ﬁeld task
was performed immediately before water maze test.
2.2. Biochemical tests
Next day after the last behavioral test, all rats were decapitated
under ether anesthesia and the brains were rapidly removed and
rinsed with ice-cold phosphate buffered saline (PBS) solution,
pH 7.4 to remove any red blood cells and clots. Then, the hippo-
campus was dissected and the following measurements were
done:
2.2.1. Hippocampal tissue levels of brain derived neurotrophic
factor (BDNF)
One half of the hippocampal tissues was homogenized in 1 ml
of the homogenization buffer (30 mM Tris–HCl, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA and 1% triton X-100 sup-
plemented with protease inhibitor cocktail). Then, the homog-
enates were centrifuged at 3000 rpm for 20 min. The
supernatants were collected and stored at 80 C after protein
level estimation by Lowry’s method.13 Level of BDNF was
determined according to the manufacturer’s ELIZA kit (Boster
Biological Technology, Fermont, California, USA).14
2.2.2. Hippocampal tissue levels of amyloid beta (Ab) peptide
The other half of hippocampal tissues was homogenized in
1 ml cold PBS (with a pH of 7.4), to which a protease inhibitor
cocktail was added. Homogenates were centrifuged at
3000 rpm for 20 min. The supernatants were collected and
stored at 80 C after protein level estimation by Lowry’s
method.13 The Ab peptide was determined according to the
manufacturer’s ELIZA kit (WKEA Med Supplies Corp.,
New York, USA (rat b-amyloid 1–42).15
2.2.3. Hippocampal tissue levels of antioxidant system:
glutathione reductase (GR), and glutathione peroxidase (GPX)
GR and GPX activities were measured in hippocampal tissues
according to the method described by Carlberg et al. 16 and
Wheeler et al.17 respectively.
GR activity was assayed spectrophotometrically, using
Trevigen Glutathione Reductase Assay Kit, wherein the oxida-
tion of NADPH to NADP was monitored as a decrease in
absorbance at 340 nm. This rate of decrease in absorbance
was directly proportional to the glutathione reductase activity
in the sample.16
Quantitative colorimetric glutathione peroxidase determi-
nation was performed using EnzyChromTM Glutathione Per-
oxidase Assay Kit (EGPX-100), wherein Cumene
hydroperoxide is reduced while reduced glutathione (GSH) is
oxidized to oxidized glutathione (GSSG). The generated
GSSG is reduced to GSH with consumption of NADPH by
130 A.R. Mohamed et al.GR. The decrease of NADPH (measured at 340 nm) was pro-
portional to GPX activity.17
2.3. Statistical analysis
The changes in the studied parameters were expressed as
mean ± SD. Differences between groups were compared by
one way ANOVA using the statistical package of social sci-
ences (SPSS) version 20. Association between different param-
eters was determined using Pearson’s correlation coefﬁcient
(r). Statistical signiﬁcance was set at p value less than 0.05.
3. Results
3.1. Alteration in cognitive performance: initial acquisition
latency (IAL), ﬁrst and second retention latency (1st and 2nd
RL) in water maze task (seconds) (Table 1 – Fig. 1)
On day 13, control ACSF-injected, vitamin D3 pre- and post-
AD treated, and vitamin D3 post-AD treated groups of rats
quickly learned to swim directly to the platform in the Morris
water maze. Untreated AD rats showed an initial increase in
IAL, which declined with continued training during the acqui-
sition of a spatial navigation task on day 13. Indeed, there was
a signiﬁcant difference in the mean IAL of untreated AD
group versus control group, on day 13, indicating that icv
injection of colchicine induced impaired acquisition of spatial
navigation task. In contrast, vitamin D3 pre- and post-AD
treated, and vitamin D3 post-AD treated rats signiﬁcantly
decreased the IAL to reach the platform in the pre-trained rats
versus untreated AD rats, on day 13 (F= 81.29, P< 0.0001).
Following training, the mean retention latencies (1st and
2nd RL) to escape onto the hidden platform were signiﬁcantly
decreased in control, untreated AD, vitamin D3 pre- and post-Table 1 Effect of icv injection of colchicine, vitamin D3 pre- and
cognitive performance in Morris water maze (seconds) in the studied
n= 10 Mean transfer latency (s)
IAL (day 13) 1s
Control 56.13 ± 5.10a 3
ACSF injected
Untreated AD 94.00 ± 6.11b 7
Vit. D3 pre- and post-AD 68.93 ± 3.59c 4
Vit. D3 post-AD 74.83 ± 6.77d 5
F1 81.29 17
P1 <0.0001* <
AD; Alzheimer’s disease, vit; vitamin, s; seconds, n, number of rats/grou
retention latency respectively.
Values are expressed as mean ± standard deviation (SD).
The letters a, to l; are called Duncan letters and are used to detect the le
In the same column, different letters indicate statistically signiﬁcant differe
the different studied groups.
F1; comparison between different studied groups at the same time.
F2; comparison between different times in the same group.AD treated, and vitamin D3 post-AD treated rats on days 14
and 21, respectively, as compared to IAL on day 13. However,
the mean of 1st and 2nd RL of untreated AD rats on days 14
and 21, respectively, were signiﬁcantly higher versus those of
the control, vitamin D3 pre- and post-AD treated, and vitamin
D3 post-AD treated rats. Regarding the AD rats, vitamin D3
pre-and post-AD treated rats signiﬁcantly decreased both 1st
and 2nd RL, on days 14 and 21, respectively, versus those of
the untreated AD and vitamin D3 post-AD treated rats
(F= 174.54, P< 0.0001 and F= 154.84, P=<0.0001,
respectively).
3.2. Hippocampal tissue levels of brain derived neurotrophic
factor (BDNF), amyloid beta (Ab) peptide (pg/mg protein)
(Table 2 – Figs. 2 and 3)
At the end of the experiment, biochemical measurement of
BDNF and Ab peptide were estimated in rat hippocampal
tissue. There was a signiﬁcant reduction in the mean values
of BDNF and a signiﬁcant increase in Ab peptide tissue lev-
els in untreated AD rats of group II, as compared to control
(ACSF injected) group I. On the other hand, pre-AD treat-
ment for one week and post-AD treatment for 3 weeks with
vitamin D3 in group III, as well as, vitamin D3 post-AD
treatment for three weeks in group IV resulted in a signiﬁ-
cant elevation of BDNF and a signiﬁcant reduction of Ab
peptide tissue levels versus untreated AD rats. However,
the signiﬁcant differences of both parameters were higher
in vitamin D3 pre- and post-AD treated rats of group III
versus vitamin D3 post-AD treated rats of group IV. Never-
theless, the mean values of BDNF and Ab peptide in rats of
groups III and IV did not reach their baseline values in con-
trol group I. (F= 62.91, P= 0.0001 and F= 45.49,
P= 0.0001, respectively).post-AD treatment and vitamin D3 post-AD treatment on the
groups.
t RL (day 14) 2nd RL (day 21) F2
P2
6.00 ± 5.81e 26.85 ± 3.64i 11.51
0.004*
9.78 ± 4.23f 76.70 ± 7.16j 6.98
0.041*
9.50 ± 3.20g 45.68 ± 3.13k 7.11
0.031*
8.15 ± 3.92h 52.70 ± 5.95l 6.85
0.042*
4.54 154.84
0.0001* <0.0001*
p, IAL; initial acquisition latency, 1st RL, 2nd RL; ﬁrst and second
ast signiﬁcant difference (LSD) in ANOVA study.
nce at p 6 0.05; p-value for F-test (ANOVA) for comparison between
Figure 1 Effect of icv injection of colchicine, vitamin D3 pre- and post-AD treatment and vitamin D3 post-AD treatment on cognitive
performance inMorris watermaze (seconds) in comparisonwith the control ACSF-injected rats; IAL, initial acquisition latency; 1st RL, 2nd
RL, ﬁrst and second retention latency respectively. Data are expressed as mean ± standard error of the mean. Number of rats/group = 10.
Table 2 Hippocampal tissue levels of brain derived neurotrophic factor (BDNF) (pg/mg protein), amyloid beta (Ab) peptide (pg/mg
protein), and activity of both glutathione reductase (GR) (nmol/min/mg protein) and glutathione peroxidase (GPX) (nmol/min/mg
protein) in the studied groups.
Control
ACSF-injected
Untreated
AD
Vit. D3 pre- and
post-AD treated
Vit. D3
post-AD treated
F
P
(n= 10)
BDNF (pg/mg protein) 629.09 ± 76.11a 305.7 ± 86.1b 501.94 ± 25.17c 386.29 ± 40.32d F= 62.91
P< 0.0001*
Ab peptide (pg/mg protein) 20.5 ± 5.6a 79.1 ± 10.8b 43.06 ± 7.13c 69.63 ± 7.91d F= 45.49
P< 0.0001*
GR (nmol/min/mg protein) 67.45 ± 6.91a 33.5 ± 7.3b 51.16 ± 5.40c 40.83 ± 3.63d F= 52.42
P< 0.0001*
GPX (nmol/min/mg protein) 12.71 ± 1.82a 6.5 ± 0.84b 9.2 ± 0.82c 7.77 ± 1.06d F= 22.77
P< 0.0001*
AD; Alzheimer’s disease, vit; vitamin, n; number of rats/group.
Values are expressed as mean ± standard deviation. In the same row, different letters indicate statistically signiﬁcant difference at p 6 0.05; p-
value for F-test (ANOVA) for comparison between the different studied groups.
The letters a, b, c, d are called Duncan letters and are used to detect the least signiﬁcant difference (LSD) in ANOVA study.
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and glutathione peroxidase (GPX) (nmol/min/mg protein)
(Table 2, Figs. 4 and 5)
At the 22nd day after colchicine AD induction, start of the
experiment, GR and GPX were measured in rat hippocampal
tissue. There was a signiﬁcant reduction in the mean values of
GR and GPX in untreated AD rats of group II, as compared
to control (ACSF injected) group I. In contrast, pre-AD treat-
ment for one week and post-AD treatment for 3 weeks with
vitamin D3 in group III, as well as, vitamin D3 post-AD treat-
ment for three weeks in group IV resulted in a signiﬁcant ele-
vation of the levels of these enzymes versus their levels in the
untreated AD rats. However, the tissue levels of GR and
GPX in group III were signiﬁcantly higher than those of group
IV. Yet, their levels in both groups III and IV were still signif-
icantly lower than those of control group I (F= 52.42,
P= 0.0001 and F= 22.77, P= 0.0001, respectively).3.4. Correlations between hippocampal tissue levels of BDNF,
Ab peptide, GR and GPX (Table 3)
The present study revealed signiﬁcant positive correlations
between the values of hippocampal tissue level of BDNF and
those of GR and GPX. On the contrary, there were signiﬁcant
negative correlations between the values of hippocampal tissue
level of Ab peptide and those of BDNF, GR and GPX
(P= 0.0001).
4. Discussion
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized by early cognitive dysfunction associ-
ated later by behavioral and social deterioration. The hippo-
campus is the primary neuronal injury region involved in the
disease pathophysiology.18 One of the prominent features of
AD, is the abnormal accumulation of b amyloid plaque.19
Figure 2 Hippocampal tissue levels of BDNF (pg/mg protein) in the studied groups. Group I: control ACSF injected, Group II: untreated
AD, Group III: vitamin D3 pre- and post-AD treated, Group IV: vitamin D3 post-AD treated. Values are expressed as mean ± SD.
Figure 3 Hippocampal tissue levels of amyloid beta peptide (pg/mg protein) in the studied groups. Group I: control ACSF injected,
Group II: untreated AD, Group III: vitamin D3 pre- and post-AD treated, Group IV: vitamin D3 post-AD treated. Values are expressed
as mean ± SD.
132 A.R. Mohamed et al.Brain-derived neurotrophic factor (BDNF) is a key target
in the pathophysiology of several neurological diseases.20 Ani-
mal models are essential tools in the elucidation of the disease
pathophysiology. One of these models is the central injection
of colchicine in the lateral ventricles, which is considered rele-
vant to cases of sporadic dementia of Alzheimer’s type inhumans.21 Hence; the goal of the present study was to clarify
the possible neuroprotective role of vitamin D3 in an animal
model of AD induced by intracerebroventricular (icv) injection
of colchicine.
Relevant ﬁndings in the present study revealed that admin-
istration of vitamin D3, pre- and post-AD induction by icv col-
Figure 4 Hippocampal tissue levels of glutathione reductase (GR) (nmol/min/mg protein) in the studied groups. Group I: control ACSF
injected, Group II: untreated AD, Group III: vitamin D3 pre- and post-AD treated, Group IV: vitamin D3 post-AD treated. Values are
expressed as mean ± SD.
Figure 5 Hippocampal tissue levels of glutathione peroxidase (GPX) (nmol/min/mg protein) in the studied groups. Group I: control
ACSF injected, Group II: untreated AD, Group III: vitamin D3 pre- and post-AD treated, Group IV: vitamin D3 post-AD treated.
Values are expressed as mean ± SD.
Neuroprotective role of vitamin D3 133chicine, improved the impaired cognition, restored the reduced
hippocampal tissue level of BDNF and antioxidants (glutathi-
one reductase GR and glutathione peroxidase GPX), as well
as, reduced the elevated hippocampal Ab peptide tissue level.
These ﬁndings illustrate that icv injection of colchicine deteri-
orates learning and memory, and induces central neuronaldamage and oxidative stress. Indeed, the present study cleared
a signiﬁcant memory impairment in Morris water maze task,
as evident by the signiﬁcant increase of initial acquisition
latency (IAL), as well as, the ﬁrst and second retention laten-
cies (1st and 2nd RL) to reach the platform in untreated rats
with AD versus control ACSF-injected rats. Furthermore in
Table 3 Correlations between hippocampal tissue levels of
brain derived neurotrophic factor (BDNF) and amyloid b (Ab)
peptide and glutathione reductase (GR) and glutathione
peroxidase (GPX) in different studied groups.
BDNF Ab peptide GR
Ab peptide 0.83**
GR 0.86** 0.85**
GPX 0.83** 0.80** 0.88**
BDNF; brain derived neurotrophic factor, Ab peptide; amyloid b
peptide, GR; glutathione reductase, GPX; glutathione peroxidase.
Pearson Correlation (2-tailed),
** Correlation is signiﬁcant at 0.01 level.
134 A.R. Mohamed et al.the untreated AD rats, there were signiﬁcant reductions of the
hippocampal tissue levels of BDNF and antioxidants, and a
signiﬁcant increase in Ab peptide versus control.
Emerich et al. 22 had reported that colchicine injection pro-
duces time and dose dependent anatomical, behavioral and
neurochemical changes maximum at 2–3 weeks following its
administration. As a tubulin inhibitor; colchicine prevents
microtubule assembly causing neuroﬁbrillary degeneration
and synaptic loss that contribute to impairment of intracellular
trafﬁcking of neurotrophic factors, axonal excitotoxicity and
oxidative damage.9,23 In the meantime, the neuronal cytoskel-
eton disruption has been linked to neuro-degeneration in AD
implementing a deleterious effect on the function and survival
of neurons.24 Meanwhile, the icv injection of colchicine does
not seem to induce signiﬁcant changes in gross behavioral
and locomotor activities in rats. This was evident from the cur-
rent results of the open ﬁeld task, where the mean scores of
gross behavioral and locomotor activities for each rat were rel-
atively stable throughout the days of the task and showed no
signiﬁcant variation among different groups.
On the other hand, the present study revealed that admin-
istration of vitamin D3 led to a signiﬁcant improvement of the
retention performance of the spatial navigation task in Morris
water maze, as evident by the signiﬁcant decrease of IAL, 1st
and 2nd RL in vitamin D3 pre- and post-AD treated and vita-
min D3 post-AD treated rats versus untreated AD rats, yet,
being more prominent in vitamin D3 pre- and post-AD treated
rats. This ﬁnding illustrates the importance of the prophylactic
use of vitamin D3 in the improvement of learning and memory
performance. In line, Mohsen et al.25 reported that vitamin D-
deprived rats had a signiﬁcantly lower performance and high-
est failures of navigation in Morris water maze versus control
rats and rats receiving vitamin D3 supplementation.
On clinical basis, some clinical studies suggest that serum
25-hydroxyvitamin D3 (25-OHD3) concentration; as an indi-
cator of vitamin D status, may be associated with dementia
and impaired cognitive function. For example, Breitling et al.26
in a study on cognition and vitamin D3 in elderly Germans,
observed that low serum levels of vitamin D3 may be associ-
ated with reduced cognitive functioning in old age. Indeed,
Oudshoorn et al.27 found that higher serum levels of vitamin
D3 are associated with better cognitive performances in
patients with AD. Similarly, Annweiler et al.28 investigated
whether the dietary intake of vitamin D could be a predictor
of the onset of dementia among elderly women and they found
that high vitamin D dietary intake was associated with a lowerrisk of developing AD among older women. On the contrary,
other clinical studies observed no linear association between
serum 25 (OH) D or vitamin D dietary intakes and incidence
of dementia or memory performance.29–31 This contradiction
could be due to diversity of the populations studied and lack
of standardized neurocognitive screening tests.
While focusing on the signiﬁcant decrease of BDNF, hippo-
campal tissue levels in untreated AD rats and its signiﬁcant rise
by vitamin D3 in pre- and post-AD treated rats, it reﬂects the
possible enrollment of BDNF as a diagnostic and prognostic
biomarker in AD, as well as, the potential neuroprotective role
of vitamin D3 through neurotrophin induction.
Aly et al.32 reported that BDNF levels were signiﬁcantly
reduced in rat model of AD induced by intraperitoneal admin-
istration of aluminum chloride (AlCl3), while Kirk et al.
33
reported that changes in serum level of BDNF might be con-
tributing to shrinkage of the hippocampus that is associated
with age related memory decline in late adulthood. Moreover,
it was found that a novel polymorphism in BDNF gene was
associated with late onset AD.34 On the contrary, Sid et al.35
found that BDNF levels did not distinguish between AD cases
and normal controls and did not signiﬁcantly predict AD
severity or global cognitive functioning in participants from
the Texas Alzheimer’s Research Consortium.
Regarding the current speculation of the possible neuropro-
tective role of vitamin D3, it is in line with evidence declaring
that vitamin D3 stimulates expression of other neurotrophic
factors as nerve growth factor, glial neurotrophic factor and
low-afﬁnity neurotrophin receptor in the brain neurons, and
glial and schwann cells.36 However, chronic administration
of vitamin D3 in rats decreased the hippocampus degenerative
processes during aging.37 Furthermore, the development of
AD is characterized by a signiﬁcant reduction of nuclear vita-
min D3 receptors.38 All these evidences suggest the importance
of the anti-degenerative activity of vitamin D3 as an underly-
ing mechanism for its neuroprotective role.
Conversely, regarding the current signiﬁcant increase of Ab
peptide hippocampal tissue levels in untreated AD rats, this
ﬁnding indicates that the neuronal cytoskeleton disruption
caused by icv injection of colchicine lead to accumulation of
Ab peptide in the hippocampus. Indeed, the abnormal accu-
mulation of Ab peptide is one of the prominent features of
AD and consequently their clearance is considered a primary
therapeutic target for managing AD. Interestingly here in, vita-
min D3 administration showed a signiﬁcant decrease in Ab
peptide hippocampal tissue levels in pre- and post-AD treated
rats, reﬂecting the possible role of vitamin D3 in enhancement
of hippocampal Ab peptide clearance and this could contribute
in the mechanism of its neuroprotective action.
In line, Shingo et al.39 found that the active form of vitamin
D appears to enhance brain to blood Ab efﬂux transport at the
blood brain barrier (BBB) leading to enhancement of its cere-
bral clearance. Similarly, Teresita et al.11 reported that vitamin
D3 supplementation modulated age-related increase in the hip-
pocampal amyloid burden by controlling the pro-inﬂamma-
tory state and increasing the activity of the amyloid
degrading enzyme in cases of age-related cognitive decline in
rats and suggested that vitamin D3 could be a useful therapeu-
tic option to alleviate the effect of aging on cognitive function.
Also, Masoumi et al.40 assuming that brain amyloidosis in AD
is related to defective clearance of Ab by innate immune sys-
tem, studied the immune stimulation of AD patients’ macro-
Neuroprotective role of vitamin D3 135phages by vitamin D3 in combination with curcuminoids.
They reported that vitamin D3 strongly stimulated Ab phago-
cytosis and clearance while protecting against apoptosis.
On the other hand, the neuroprotective role of vitamin D3,
currently assumed in the present study, could be resorted to its
possible antioxidant effect as evidenced by the signiﬁcant rise
of hippocampal tissue levels of the antioxidant enzymes GR
and GPX in vitamin D3 pre- and post-AD treated rats. As evi-
denced in the literature, oxidative stress had been implicated in
the neurodegenerative process in AD, which may be either due
to excessive production of free radicals or loss of antioxidant
defenses or both.41 Loss of glutathione had been suggested
as an early signaling event in mitochondrial dysfunction and
apoptotic cell death involved in neurodegeneration and aging
process. Hence, glutathione replenishment had been proposed
as one of the therapeutic targets in some of the neurodegener-
ative disorders, but as it does not cross BBB, thus, glutathione
enhancers or analogues are discussed.42 Vitamin D3 is in con-
cern; as it had been related to up-regulation of the activity and
expression of brain gamma glutamyl transpeptidase; a key
enzyme involved in brain glutathione cycle, thus it ameliorates
the antioxidant defense by increasing brain glutathione.43
Moreover, it had been reported that vitamin D3 inhibits the
expression of inducible nitric oxide synthase (iNOS) that is
thought to play a role in AD pathogenesis; as iNOS-positive
neurons were detected in 100% of the AD brains studied
and were linked to Ab peptide.44,45 In the meanwhile, vitamin
D3 had been demonstrated to interact with reactive oxygen
and nitrogen species in various models of brain oxidative chal-
lenges, suggesting its role in brain detoxiﬁcation pathways.46–48
It is noteworthy tomention that, in the present study, the pro-
phylactic use of vitamin D3 in rats before induction of AD had
yielded more signiﬁcant ﬁndings in all parameters versus rats
receiving vitamin D only after AD induction. This ﬁnding could
highlight the importance of replenishment of brain vitamin D3
stores to guard against substantial neuronal damage; including
aging process, ischemic insult, oxidative stress or degenerative
illnesses. Indeed, the associationbetween serumvitaminD3 level
and cognitive impairment emphasizes the importance of micro-
nutrients in the elderly population.49 Likewise, Yu et al.50
reported that vitaminD3 enriched diet correlateswith a decrease
in the number of amyloid plaques and inﬂammation, and
increase in nerve growth factor in the brain of amyloid-beta pro-
tein precursor (AbPP) transgenic mice.
Generally, vitamin D receptors are widely distributed in the
cortex and hippocampus, and accumulating data provide evi-
dence for unpredicted roles for vitamin D in brain develop-
ment and function.8–11 Since causal relationship between
vitamin D level and pathogenesis of AD had been largely spec-
ulated, it is possible that vitamin D supplement, in elderly or in
individuals at risk of AD, could allow more circulating hor-
mone providing neuroprotection and guard against cognitive
decline. Further research is warranted to inquire the safety
and cost-effectiveness of vitamin D supplement in elderly to
reduce safe way of reducing the incidence of cognitive impair-
ment in the growing elderly population around the world.
5. Conclusion
Based on data presented in this study, it can be concluded that
the active form of vitamin D3 could have a neuroprotectiveeffect in AD that involves many mechanisms; including
increase of hippocampal neurotrophic factors as BDNF, rise
of the antioxidant defense system, as well as, reduction of
the burden of Ab peptide leading to improvement of the cog-
nitive functions. Hence, vitamin D3 or its analogues could be
considered as promising agents for the development of new
prophylactic and therapeutic neuroprotectors.
Conﬂict of interest
We have no conﬂict of interest to declare.
References
1. De la Torre JC. Is Alzheimer’s disease a neurodegenerative or a
vascular disorder? Data, dogma, and dialectics. Lancet Neurol
2004;3:184–90.
2. Gotz J, Ittner M. Animals models of Alzheimer’s disease and
frontotemporal dementia. Nat Rev Neurosci 2008;9(7):532–44.
3. Kumar A, Dogra S, Prakash A. Protective effect of narining, a
citrus ﬂavonoid against colchicine- induced cognitive dysfunction
and oxidative damage in rats. J Med Food 2010;13(4):976–84.
4. Kumar A, Seghal N, Naidu PS, Padi SS, Goval R. Colchicine-
induced neurotoxicity as an animal model of sporadic dementia of
Alzheimer’s type. Pharmacol Rep 2007;59(3):274–83.
5. Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LM,
Moreira WL, et al. Peripheral oxidative stress biomarkers in mild
cognitive impairment and Alzheimer’s disease. J Alzheimer’s Dis
2011;26(1):59–68.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s
disease: progress and problems on the road to therapeutics.
Science 2002;297:353–6.
7. Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K,
Tachikawa M, et al. Brain insulin impairs amyloid- beta clearance
from the brain. J Neurosci 2004;24:9632–7.
8. Llewellyn DJ, Langa KM, Lang IA. Serum 25-hydroxyvitamin D
concentration and cognitive impairment. J Geriatr Psychiatry
Neurol 2009;22:188–95.
9. Kumar Veerenda MH, Gupta YK. Intracerebroventricular admin-
istration of colchicine produces cognitive impairment associated
with oxidative stress in rats. Pharmacol Biochem Behav
2002;73:565–71.
10. Kumar A, Dogra S, Prakash A. Neuroprotective effect of Centella
Asiatica against intracerebroventricular colchicine-induced cogni-
tive impairment and oxidative stress. Int, J Alzheimers Dis
2009.pii:972178.
11. Teresita LB, Darwish H. Vitamin D mitigates age-related cogni-
tive decline through the modulation of pro-inﬂammatory state and
decrease in amyloid burden. J Neuroinﬂammation 2012;9:244.
12. Ja¨hkel M, Rilke O, Koch R, Oehler J. Open ﬁeld locomotion and
neurotransmission in mice evaluated by principal component
factor analysis-effects if housing condition, individual activity
disposition and psychotropic drugs. Prog Neuropsychopharmacol
Biol Psychiatry 2000;24:61–84.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein
measurement with the folin phenol reagent. J Biol Chem
1951;193:265–75.
14. Dekel T, Assaf L, Roman G, Sharon Hi, Alon C. Resilience to
chronic stress is mediated by hippocampal brain-derived neuro-
trophic factor. J Neurosci 2011;31(12):4475–83.
15. Zhao Z, Ho L, Wang J, Qin W, Festa ED, Mobbs C, et al.
Connective tissue growth factor(CTGF) expression in the brain as
a downstream effector of insulin resistance-associated promotion
of Alzheimer’s disease beta-amyloid neuropathology. FASEB J
2005;19(14):2081–2.
136 A.R. Mohamed et al.16. Carberg I, Mannerviek B. Glutathione reductase levels in rat
brain. J Biol Chem 1975;250:5475–80.
17. Wheeler CR, Salzman JA, Elsayed NM, Omaye ST, Korte DW.
Automated assay for superoxide dismutase, catalase, glutathione
peroxidase and glutathione reductase activity. Anal Biochem
1990;184:193–9.
18. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW.
The topographical and neuroanatomical distribution of neuroﬁ-
brillary tangles and neuritic plaques in the cerebral cortex of
patients with Alzheimer’s disease. Cereb Cortex 1991;1:103–16.
19. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauop-
athies. Annu Rev Neurosci 2001;24:1121–59.
20. Diniz BS, Teixera AL. Brain-derived neurotrophic factor and
Alzheimer’s disease: physiopathology and beyond. Neuromol Med
2011;13(4):217–22.
21. Bensimon G, Chermat R. Microtubule disruption and cognitive
defects: effect of colchicine on learning behavior in rats. Pharmacol
Biochem Behav 1991;38:141–5.
22. Emerich DF, Walsh TJ. Cholinergic loss and cognitive impairment
following intraventricular or intradentate injections of colchicines.
Brain Res 1990;517:57–167.
23. Sharma M, Gupta YK. Intracerebroventricular injection of
streptozotocin in rats produces both oxidative stress in the brain
and cognitive impairment. Life Sci 2001;19 6(9):1021–9.
24. Lee VM, Trojanowski JQ. The disordered neuronal cytoskeleton
in Alzheimer’s disease. Curr Opin Neurobiol 1992;2(5):653–6.
25. Mohsen T, Sayyed AT, Mahmoud S. Vitamin D deﬁciency impairs
spatial learning in adult rats. Iran Biomed J 2013;17(1):42–8.
26. Breitling LP, Perna L, Muller H, Raume E, Kliegel M, Brenner H.
Vitamin D and cognitive functioning in the elderly population in
Germany. Exp Gerontol 2012;47(1):122–7.
27. Oudshoorn C, Mattace-Raso FU, van der Velde N, Colin EM,
van der Cammen TJ. Higher serum vitamin D3 levels are
associated with better cognitive test performance in patients with
Alzheimer’s disease. Dement Geriatr Cogn Disord
2008;25(6):539–43.
28. Annweiler C, Rolland Y, Schott AM, Blain H, Vellas B,
Herrmann FR, et al. Higher vitamin dietary intake is associated
with lower risk of Alzheimer’s disease: a 7- year follow up. J
Gerontol A Biol Sci Med Sci 2012;67(11):1205–11.
29. McGrath J, Scragg R, Chant D, Eyles D, Burne T, Obradovic D.
No association between serum 25-hydroxyvitamin D3 level and
performance on psychometric tests in NHANES III. Neuroepi-
demiology 2007;29:49–54.
30. Nes M, Sem SW, Rousseau B, Bjørneboe GE, Engedal K, Trygg
K, et al. Dietary intakes and nutritional status of old people with
dementia living at home in Oslo. Eur J Clin Nutr
1988;42(7):581–93.
31. Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsy-
chological function in relation to serum parathyroid hormone and
serum 25-hydroxyvitamin D levels. The Tromso study. J Neurol
2006;253:464–70.
32. Aly HF, Metwally FM, Ahmed HH. Neuroptective effect of
dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s
disease. Acta Biochim Pol 2011;58(4):513–20.
33. Kirk L, Ruchika S, Michelle W, Laura C, Suise H, Molly M, et al.
Brain derived neurotrophic factor is associated with age-related
decline in hippocampal volume. J Neurosci 2010;30(15):5368–75.
34. Kunugi H, Ueki A, Otsuka M, Isse K, Kato N, Nabika T. A novel
polymorphism of the Brain derived neurotrophic factor (BDNF)gene associated with late-onset Alzheimer’s disease. Mol Psychi-
atry 2001;6(1):83–6.
35. Sid E, Valerie H, James R, Stephen C, Wenyan C, Chan W, et al.
Brain-derived neurotrophic factor levels in Alzheimer’s disease. J
Alzheimers Dis 2009;17(2):337–41.
36. Eyles D, Brown J, Mackay-Sim A, Macgrath J, Feron F. Vitamin
D3 and brain development. Neuroscience 2003;118:641–53.
37. Kalueff AV, Eremin KO, Tuohimaa P. Mechanisms of neuropro-
tective action of vitamin D3. Biochemistry (Moscow)
2004;69(7):907–11.
38. Sutherland MK, Somerville MJ, Yoong LK, Bergeron C, Haussler
DR, McLachlan DR. Reduction of vitamin D hormone receptor
mRNA levels in Alzheimer as compared to Huntington hippo-
campus: correlation with calbindin-28k mRNA levels. Brain Res
Mol Brain Res 1992;13:239–50.
39. Shingo L, Sumio O, Yasuko N, Yusuke K, Sho M, Testsuya T.
1a,25-dihydroxyvitamin D3 enhances cerebral clearance of human
amyloid-b peptide(1–40) from mouse brain across the blood-brain
barrier. Fluids Barriers CNS 2011;8:20–9.
40. Masoumi A, Goldenson B, Ghirmai S, Avagyan A, Zaghi J,
Abel K, et al. 1 alpha, 25-dihydroxyvitamin D3 interacts with
curcuminoids to stimulate amyloid-beta clearance by macro-
phages of Alzheimer’s disease patients. J Alzheimer’s Dis
2009;17(3):703–17.
41. Perry G, Cash AD, Smith MA. Alzheimer’s disease and oxidative
stress. J Biomed Biotechnol 2002;2:120–3.
42. Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione,
oxidative stress and neurodegeneration. Eur J Biochem
2000;267:4904–11.
43. Garcion E, Wion-Barbot N, Montero-Menei C, Berger F, Wion
D. New clues about vitamin D in the nervous system. Trends
Endocrinol Metab 2002;13:100–5.
44. Nataf S, Garcion E, Darcy F, Chabannes D, Muller JY, Brachet
P. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible
nitric oxide synthase in rat nervous system during experimental
allergic encephalomyelitis. Mol Brain Res 1997;45:255–67.
45. Vodoyotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith
TW, et al. Inducible nitric oxide synthase in tangle-bearing
neurons of patients with Alzheimer’s disease. J Exp Med
1996;184:1425–33.
46. Harmes LR, Brunet H, Eyles DW, McGrath TJ. Vitamin D and
the brain: best practice & research. Clinical Endocrinol Metab
2011;25(4):657–69.
47. Shinpo K, Kikuchi S, Sasaki H, Moriwaka F, Tashiro K. Effect
of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic neu-
rons to the combined toxicity caused by L-buthionine sulfox-
imine and 1-methyl-4-phenylpyridine. J Neurosci Res
2000;62:374–82.
48. Brewer IL, Thibauli V, Chen K, Langub M, Landﬁeld P, porter N.
Vitamin D hormone confers neuroprotection in parallel with down
regulation of L-type calcium channels expression in hippocampus.
J Neurosci 2001;21:98–108.
49. McCann JC, Ames BN. Is there convincing biological or behav-
ioral evidence linking vitamin D deﬁciency to brain dysfunction?
FASEB J 2008;22:982–1001.
50. Yu J, Gattoni CM, Zhu H, Sambamurti K, Gattoni CS, Kindy
MS. Vitamin D3 enriched diet correlates with a decrease of
amyloid plaques in the brain of Ab PP transgenic mice. J
Alzheimers Dis 2011;25(2):295–307.
